Pediatric fever of uncertain source: Difference between revisions
No edit summary |
|||
| Line 168: | Line 168: | ||
|} | |} | ||
=== 28dy-90dy=== | === 28dy-90dy === | ||
{| style="width: 495px; height: 103px" cellspacing="1" cellpadding="1" width="495" border="1" | {| style="width: 495px; height: 103px" cellspacing="1" cellpadding="1" width="495" border="1" | ||
| Line 178: | Line 178: | ||
| '''Follow Up''' | | '''Follow Up''' | ||
|- | |- | ||
| '''T | | '''T>=38 + Toxic''' | ||
| | | | ||
#CBC | #CBC | ||
#Blood Cx | #Blood Cx | ||
| Line 185: | Line 185: | ||
#LP-CSF | #LP-CSF | ||
#CXR (only if resp sx) | #CXR (only if resp sx) | ||
| | | | ||
#Cefotaxime^ 50-100 mg/kg | #Cefotaxime^ 50-100 mg/kg | ||
#Ampicillin 100 mg/kg | #Ampicillin 100 mg/kg | ||
#Acyclovir^^ 20 mg/kg | #Acyclovir^^ 20 mg/kg | ||
| Admit | | Admit | ||
| NA | | NA | ||
|- | |- | ||
| | | | ||
'''T | '''T>=38 + Well''' | ||
'''(Option 1)''' | '''(Option 1)''' | ||
| CBC <br>Blood Cx <br>UA, Ucx <br>LP-CSF <br>CXR (only if resp sx) <br> | |||
| Ceftriaxone (50mg/kg IM/IV) | |||
| | | | ||
If W/U + admit | |||
| | Outpatient^^^ | ||
| If W/U negative, meets outpt | |||
|- | |- | ||
| | | | ||
'''T | '''T>=38 + Toxic''' | ||
'''(Option 2)''' | '''(Option 2)''' | ||
| CBC <br>Blood Cx <br>UA, Ucx <br>CXR (only if resp sx) <br> | |||
| | | | ||
None | |||
For very well appearing 60-90 day olds (many would not use) | |||
| Outpatient^^^ | | Outpatient^^^ | ||
| | | | ||
|} | |} | ||
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1" | {| style="width: 500px" cellspacing="1" cellpadding="1" border="1" | ||
| Line 268: | Line 282: | ||
|- | |- | ||
| | | | ||
57d-6mo, ≥38 | <br> | ||
<br>57d-6mo, ≥38 | |||
Non-UTI SBI incidence is estimated to be negligible | Non-UTI SBI incidence is estimated to be negligible | ||
Revision as of 19:46, 28 July 2012
From Tintinalli
Management of patients who are well-appearing, vaccinated, and no clinical source of fever
| Age Group | Evaluation | Treatment |
|
0-28d, ≥38C SBI incidence of ill appearing: 13%–21% if not ill appearing: <5% |
CBC, blood Cx UA, Ucx CSF cell count, GS, Cx CXR (only if resp sx) Stool testing (if diarrhea present) |
Admit Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) |
|
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)
if not ill appearing: <5%
|
Same as for neonates |
Discharge if: 1. WBC <15K but >5K and <20% bands 2. UA negative Admit and perform LP if above are not met Treat with CTX 50mg/kg (if CSF normal), 100mg/kg (if signs of meningitis) |
|
57d-6mo, ≥38 Non-UTI SBI incidence is estimated to be negligible UTI is 3%–8%
|
UA and Ucx alone OR treat 57-90d using Philadelphia Protocol |
Discharge if negative Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient Admit and tx with CTX if fail criteria for d/c |
|
57d-6mo, ≥39 (102.2) SBI incidence is estimated <1%; non-UTI SBI incidence is estimated to be negligible. UTI is 3%–8% |
UA and Ucx alone OR UA and Ucx + CBC + blood cx |
Discharge if negative Treat for UTI as above If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr If WBC>20K consider CXR and CSF |
|
6–36 mo Non-UTI SBI incidence is <0.4% UTI in girls ≤8% UTI in boys (<12 mo) ≤ 2% Uncircumcised boys (1–2 y) remains 2% |
UA and Ucx in: (girls 6-24mo) (circ 6-12mo) (uncirc 6-24mo) |
Discharge if negative Treat for UTI as above as outpatient |
| >36mo | No further w/u is routinely necessary |
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d
Harbor-UCLA Protocol
0-28dy
| Child Appearance | Work Up | Treatment | Disposition | Follow Up |
| T>=38
Toxic or Well |
|
|
Admit | N/A |
28dy-90dy
| Appearance | Work Up | Treatment | Disposition | Follow Up |
| T>=38 + Toxic |
|
|
Admit | NA |
|
T>=38 + Well (Option 1) |
CBC Blood Cx UA, Ucx LP-CSF CXR (only if resp sx) |
Ceftriaxone (50mg/kg IM/IV) |
If W/U + admit Outpatient^^^ |
If W/U negative, meets outpt |
|
T>=38 + Toxic (Option 2) |
CBC Blood Cx UA, Ucx CXR (only if resp sx) |
None For very well appearing 60-90 day olds (many would not use) |
Outpatient^^^ |
| Age Group | Evaluation | Treatment |
|
T>=38 + Toxic |
|
Discharge if:
Admit if:
|
|
T>=38 + Well |
|
Discharge if:
Admit if:
|
|
Non-UTI SBI incidence is estimated to be negligible |
UA and Ucx alone OR treat 57-90d using Philadelphia Protocol |
Discharge if negative Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient Admit and tx with CTX if fail criteria for d/c |
|
57d-6mo, ≥39 (102.2) SBI incidence is estimated <1%; non-UTI SBI incidence is estimated to be negligible. UTI is 3%–8% |
UA and Ucx alone OR UA and Ucx + CBC + blood cx |
Discharge if negative Treat for UTI as above If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr If WBC>20K consider CXR and CSF |
90dy-36mo
| Age Group | Evaluation | Treatment |
|
57d-6mo, ≥39 (102.2) SBI incidence is estimated <1%; non-UTI SBI incidence is estimated to be negligible. UTI is 3%–8% |
UA and Ucx alone OR UA and Ucx + CBC + blood cx |
Discharge if negative Treat for UTI as above If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr If WBC>20K consider CXR and CSF |
|
6–36 mo Non-UTI SBI incidence is <0.4% UTI in girls ≤8% UTI in boys (<12 mo) ≤ 2% Uncircumcised boys (1–2 y) remains 2% |
UA and Ucx in: (girls 6-24mo) (circ 6-12mo) (uncirc 6-24mo) |
Discharge if negative Treat for UTI as above as outpatient |
| >36mo | No further w/u is routinely necessary |
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d
^Can use ceftriaxone 50-100 mg/kg, but concern for bilirubin displacement ^^Add acyclovir if HSV infection in baby or mother, CSF pleocytoisis, concerning skin lesions, seizures, abnl LFTs
See Also
Source
Tintinalli
